Fatal Acute Pancytopenia Following Tridione Treatment

TRIDIONE, since first proposed in 1945 as an anticonvulsant agent, has been generally accepted for the control of petit-mal and major psychomotor attacks. The favor it met with was justified by a number of reports, all claiming the efficiency of the drug in the control of convulsive disorders and the apparent absence of toxic manifestations. No side effects were seen by Everett and Richards1 in a large series of animals, including mice, guinea pigs, cats and rabbits, in which the anticonvulsant properties of the new drug were compared with those of Dilantin and phenobarbital; no toxic manifestations were found by . . .